biostudies-literatureZhuang PYoung Elite Scientists Sponsorship Program by CASNatural Science Foundation of Zhejiang ProvinceNational Natural Science Foundation of China52https://www.ebi.ac.uk/biostudies/studies/S-EPMC12905938biostudies-literatureUnknown25(1)<h4>Background</h4>Carotid plaques result from a blockage or narrowing of carotid arteries associated with severe atherosclerotic cardiovascular diseases. We aimed to assess the effect of marine n-3 fatty acid supplementation on carotid plaques among patients with diabetes and whether the effect was modified by genetics.<h4>Methods</h4>In this 14 month double-blind, randomized controlled trial, 415 patients with type 2 diabetes (T2D) were randomly assigned to receive high-dose (3.0 g/day) or low-dose (1.5 g/day) marine n-3 fatty acids (fish oil) or placebo (refined olive oil). The primary outcome was the prevalence of carotid plaques. Secondary outcomes included changes in NMR-derived lipoprotein subclasses. Genetic interactions with the supplementation were also explored.<h4>Results</h4>3Cardiovascular diabetologyMarine n-3 fatty acid treatment for carotid plaques in patients with type 2 diabetes.PMC129059382022QNRC0013220205781773419LY23C200007Zhang FWang AWan XZhang LJiao JWu FLiu XChen WAo YWu SJia WGu JWu YYu XWu XZhuang PLi HZhu FZheng WLan XTong WLi YMeng DZhu LZhang YTian YYe HShi HfalseMarine n-3 fatty acid treatment for carotid plaques in patients with type 2 diabetes.<h4>Background</h4>Carotid plaques result from a blockage or narrowing of carotid arteries associated with severe atherosclerotic cardiovascular diseases. We aimed to assess the effect of marine n-3 fatty acid supplementation on carotid plaques among patients with diabetes and whether the effect was modified by genetics.<h4>Methods</h4>In this 14 month double-blind, randomized controlled trial, 415 patients with type 2 diabetes (T2D) were randomly assigned to receive high-dose (3.0 g/day) or low-dose (1.5 g/day) marine n-3 fatty acids (fish oil) or placebo (refined olive oil). The primary outcome was the prevalence of carotid plaques. Secondary outcomes included changes in NMR-derived lipoprotein subclasses. Genetic interactions with the supplementation were also explored.<h4>Results</h4>32026-01-01T00:00:00Z2026 Jan2026-07-15T21:31:00.115Z2026-07-09T10:14:06.882ZS-EPMC129059384155969810.1186/s12933-026-03082-7